View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 13, 2022

Worldwide Clinical Trials, Invitae partner to expedite rare disease trials

Worldwide will have access to data insights based on demographics, geography, incidence and epidemiology for rare diseases.

Worldwide Clinical Trials has entered a strategic collaboration with medical genetics company Invitae to expedite clinical trials for rare disease patients.

Under the collaboration, Worldwide will leverage Invitae’s Explorer tool, which is part of its real-world data platform that offers access to combined genetic testing results.

With the latest development, Worldwide will become the first contract research organisation (CRO) to use the Explorer tool.

The company will also have access to data insights based on demographics, geography, prevalence, incidence and epidemiology for patients with rare diseases, under this deal. 

With this combined data, Worldwide will be able to recruit participants rapidly and locate the best trial locations to aid its sponsors find new and potentially life-saving therapies for rare disease patients.

Invitae co-founder and CEO Sean George said: “Our strategic collaboration enables Worldwide to gain valuable insight into the genetic etiology of rare disease to help shape and improve the future of clinical trials. 

“Our cutting-edge tools empower Worldwide with the opportunity to set clinical trial strategies based on specific disease and geographic prevalence to yield the data needed to treat genetic disorders globally.”

Furthermore, through access to combined genetic testing data of Invitae, Worldwide has improved its expertise to tackle the complications of rare disease trials through enhanced visibility of where patients are.

This ultimately aids the CRO in offering essential and meaningful treatments.

Worldwide Clinical Trials president and co-CEO Peter Benton said: “Our unique access to Invitae’s database provides us with superior visibility to an aggregate-level view of patients we otherwise wouldn’t be aware of and enables us to offer advanced clinical trial strategies to our sponsors. 

“This also helps us boost much-needed patient recruitment efforts, expanding our reach and ability to connect the right patients with the right clinical trial opportunities.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena